Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.
- Five complete responses (7.8%) confirmed in ACCENT trial
- Median overall survival extended to 11.1 months
- Objective response rate updated to 35.9%
- No additional toxicity observed with narmafotinib combination
- Data to be presented at AACR 2026 in San Diego
Amplia’s ACCENT Trial Delivers Promising Pancreatic Cancer Data
Amplia Therapeutics has unveiled compelling new results from its ACCENT clinical trial, investigating narmafotinib combined with chemotherapy in advanced pancreatic cancer. The latest independent analysis confirms an unprecedented 7.8% complete response rate among patients, alongside a median overall survival of 11.1 months; a notable improvement over chemotherapy alone.
This Phase 1b/2a trial enrolled 64 patients receiving a 400 mg dose of narmafotinib alongside the standard gemcitabine and Abraxane chemotherapy regimen. An expert central laboratory re-evaluated the clinical data, identifying four additional complete responses beyond those initially reported by trial sites. This brings the total to five complete responses, a figure rarely seen in this aggressive cancer type.
Survival Gains Without Added Toxicity
Median overall survival (mOS) reached 11.1 months, representing a two-month extension compared to historical data from the MPACT trial, which established gemcitabine-Abraxane as the standard of care. This survival benefit matches outcomes seen with the recently approved NALIRIFOX combination, underscoring narmafotinib’s potential as a valuable addition to pancreatic cancer treatment.
Importantly, the safety profile remains favourable, with no increase in toxicity observed when narmafotinib is combined with chemotherapy. This suggests patients can potentially gain survival benefits without compromising quality of life.
Broader Implications and Next Steps
Amplia’s CEO, Dr Chris Burns, emphasised the significance of these findings, highlighting the hope they offer patients facing this notoriously difficult-to-treat cancer. The company plans to present a detailed analysis of the ACCENT trial at the upcoming American Association of Cancer Research (AACR) meeting in April 2026, a prestigious platform that could attract further attention from the oncology community and investors alike.
Meanwhile, the ongoing AMPLICITY trial is exploring narmafotinib in combination with the FOLFIRINOX chemotherapy regimen, potentially broadening its clinical application. With four patients still on study and one approaching two years on treatment, longer-term data will be critical to fully understand the durability of responses.
Amplia’s progress with narmafotinib reflects a growing focus on targeting Focal Adhesion Kinase (FAK), a protein implicated in cancer progression and fibrosis. As the company advances its pipeline, these encouraging ACCENT results could pave the way for regulatory milestones and partnerships.
Bottom Line?
Amplia’s ACCENT trial data marks a hopeful advance in pancreatic cancer treatment, but the path to regulatory approval and broader adoption remains to be charted.
Questions in the middle?
- Will longer-term survival data sustain the early promising trends?
- How will regulatory agencies respond to these updated ACCENT results?
- What impact will narmafotinib have compared to emerging pancreatic cancer therapies?